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Abstract. Eradicating measles represents a major public health 
achievement, yet outbreaks still occur in territories where endemic 
measles virus (MV) had been eliminated. In Catalonia from the 
year 2000 cases have occurred as isolated cases or small outbreaks,  
both linked to imported cases up to the end of  2006 when a large 
outbreak started out affecting mainly children ≤15m. In consequence, 
immunization schedule was amended lowering first dose to 12m. 
Again new MV importations from neighboring countries triggered 
another outbreak on November 2010 with a different age 
distribution sparing small children from infection. Differences in 
incidence (IR), rate ratio (RR) and 95% CI and hospitalization rate 
(HR) by age group were determined. Statistic z was used for 
comparing proportions.  Total number of confirmed cases was 305 
vs 381 in 2006; mean age 20 yrs (SD 14.8yrs; 3m -51yrs) vs                     
15m (SD13.1yrs; 1m-50yrs).  Highest proportion of cases                    
was set in ≥25yrs (47%) vs 24.2% in 2006 (p<0.001). Difference in  
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IR for ≤ 15m was statistically significant (49/100,000 vs 278.2/100,000; RR:3.9; 
95%CI 2.9-5.4) and in HR 30.2% vs 15.7% (p<0.001). The change of the month of 
administration of the first dose proved successful. Given the current epidemiological 
situation, continued awareness and efforts to reach young adult population are needed 
to stop the spread of the virus.  
                                                                                                                                                  
Introduction 
 
 Eradicating measles represents a major public health achievement, yet  
outbreaks still occur in territories where endemic measles virus (MV) had  
been eliminated. In theory, if the right tools were available, all infectious 
diseases would be eradicable. In reality, there are distinct biological features 
of the organisms and technical factors of dealing with them that make their 
potential eradicability more or less likely. Today's categorization of a disease 
as not eradicable can change completely tomorrow, either because research 
efforts are successful in developing new and effective intervention tools or 
because those presumed obstructions to eradicability that seemed important 
in theory prove capable of being overcome in practice. Three indicators were 
considered to be of primary importance: an effective intervention is available 
to interrupt transmission of the agent; practical diagnostic tools with 
sufficient sensitivity and specificity are available to detect levels of infection 
that can lead to transmission; and humans are essential for the life-cycle of 
the agent, which has no other vertebrate reservoir and does not amplify in the 
environment [1]. 
 The effectiveness of an intervention tool has both biological and 
operational dimensions. Elimination validates the effectiveness of an 
intervention tool, but it does not necessarily make the agent a candidate for 
eradication. Highly developed levels of sanitation and health systems 
development may make elimination possible in one geographical area but not 
in another. 
 Diagnostic tools also have both biological and operational dimensions. 
The tools must be sufficiently sensitive and specific to detect infection that 
can lead to transmission, and also sufficiently simple to be applied globally 
by laboratories with a wide range of capabilities and resources. Eradication is 
a much more feasible target of deliberate intervention when humans form an 
essential component of the agent's life-cycle. An independent reservoir is not 
an absolute barrier to eradication if it can be targeted with effective 
intervention tools. 
 The costs and benefits of global eradication programmes can be grouped 
into two categories: direct effects and consequent effects. The direct effects 
of eradication are that no morbidity or mortality due to that disease will ever 
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again occur. Explicit efforts should be taken to maximize the effectiveness of 
both eradication and comprehensive health programmes [2]. 
 Eradication has been defined in various ways: as extinction of the disease 
pathogen, as elimination of the occurrence of a given disease, even in the 
absence of all preventive measures, as control of an infection to the point at 
which transmission ceased within a specified area, and as reduction of the 
worldwide incidence of a disease to zero as a result of deliberate efforts, 
obviating the necessity for further control measures. The hierarchy of 
potential public health efforts in dealing with infectious diseases was 
discussed at the Dahlem Workshop. Differences in these efforts made a 
distinction between the disease caused by the infection and the infection 
itself, the level of reduction achieved for either of these, the requirement for 
continuation of control efforts, and, finally, the geographical area covered by 
the intervention efforts and their outcomes. Although definitions outlined 
below were developed for infectious diseases, those for control and 
elimination apply to noninfectious diseases as well [3]. 
 
 Control: The reduction of disease incidence, prevalence, morbidity or 
mortality to a locally acceptable level as a result of deliberate efforts; 
continued intervention measures are required to maintain the reduction. 
Example: diarrheal diseases.  
 Elimination of disease: Reduction to zero of the incidence of a specified 
disease in a defined geographical area as a result of deliberate efforts; 
continued intervention measures are required. Example: neonatal tetanus.  
 Elimination of infections: Reduction to zero of the incidence of infection 
caused by a specific agent in a defined geographical area as a result of 
deliberate efforts; continued measures to prevent re-establishment of 
transmission are required. Example: poliomyelitis.  
 Eradication: Permanent reduction to zero of the worldwide incidence of 
infection caused by a specific agent as a result of deliberate efforts; 
intervention measures are no longer needed. Example: smallpox.  
 Extinction: The specific infectious agent no longer exists in nature or in 
the laboratory. (There is no example yet) [2]. 
 
 Globally, about 25% of disease morbidity and mortality are attributable 
to communicable diseases. In developed countries communicable diseases 
have decreased in a remarkable way because of antibiotics and vaccines. 
 One of these candidate diseases to be eliminated and ultimately 
eradicated is measles [4]. Measles  is a highly transmissible disease for which 
conditions for eradication are favorable: humans are the only reservoir for the 
measles virus (MV), the vaccine is safe, inexpensive and produces life-long 
immunity, diagnostic tests are both specific and sensitive, all infected people 
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develop symptoms, and there are no chronic carriers [4,5]. Eradicating 
measles would represent a major public health achievement, well worth the 
investment it requires. For the EU, the first step towards eradication of 
measles is effective control within its own borders.  Finally, eradication will 
be the result of elimination of transmission on all continents. Elimination of 
measles by 2015 is part of the WHO strategic plan for measles in the World 
Health Organization (WHO) European Region. 
 Measles is caused by a single-stranded RNA virus of the genus 
Morbillivirus in the family Paramyxoviridae characterized in 1954 by Enders 
and Peebles with 23 known genotypes. It is spread by droplets or direct 
contact with nasal or throat secretions of infected persons; less commonly by 
airborne spread or by articles freshly soiled with secretions of nose and 
throat. Measles is one of the most readily transmitted communicable diseases 
and probably the best known and most deadly of all childhood rash/fever 
illnesses. Measles is characterized by rash, fever, and cough, coryza or 
conjunctivitis and is transmitted by pharyngeal or nasal secretions, normally 
from four days before to four days after the onset of rash. The incubation 
period is normally 10-14 days and the possible complications include otitis 
media, laryngotracheobronchitis, pneumonia, diarrhea, encephalitis and 
secondary bacterial infections. Children aged < 5 years who are living in poor 
conditions or are malnourished, and adults or patients with immune 
deficiencies have a greater risk of severe complications [6]. Subacute 
sclerosing panencephalitis (SSPE), a degenerative neurological disease that 
occurs several years after infection is the most severe condition related to 
measles infection especially in the very young. The increased risk of 
developing SSPE after measles virus infection in young children underscores 
the importance of childhood immunization programs that decrease measles 
virus transmission and, therefore, reduce the risk of exposure to measles 
among infants and  prevent the devastating disease SSPE [7].  Measles can be 
effectively prevented by vaccination which provides lifelong immunity to 
most recipients against all 23 recognized genotypes.  
 High immunization coverage has dramatically reduced the incidence of 
measles in Catalonia since measles vaccine was included in vaccination 
schedule in 1981. Despite overall high vaccination coverage, measles 
continues to cause frequent outbreaks. However, given the current 
epidemiological situation [8-12], continued awareness and efforts are needed.  
Especial efforts should be set concerning mass-gathering events and high 
travelling frequency among their population as well as from other parts of the 
world which offer favorable conditions for the spread of the virus between 
countries.  
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 In Catalonia, a region in the Northeast of Spain with a population of 
more than 7.5 million inhabitants, autochthonous measles was declared 
eliminated in the year 2000 [13] as the result of high Measles Mumps Rubella 
vaccine (MMR) coverage for first and second dose (15 months and 4 years.) 
since mid 90’s, from then on then sporadic imported cases and small 
outbreaks appeared until  August  2006, when a large measles outbreak 
appeared  affecting 381 people,  50% of which were below 15 months of age 
[14]. From January 2008 first dose administration of MMR was in 
consequence lowered to 12 months of age. A new honeymoon period went by 
until at the end of 2010, again, several new importations of different 
genotypes of wild MV, from neighboring countries triggered another 
outbreak on November 2010 with a different age distribution sparing small 
children from infection and striking young adults, mainly  adults  >25 years.  
 The aim of this study is to compare differences in age distribution and 
incidence rates (IR) of cases resulting from first dose MMR vaccine 
administration changed from 15months to 12months of age and to underscore 
the importance of enhanced surveillance and implementation of actions to 
prevent disease and hospitalization for all ages and especially in hard to reach 
susceptible population. 
 
1. Material and methods 
  
 Urgent reported suspected cases of measles to the Public Health 
Surveillance units were registered and   data on age, vaccination status, 
clinical course and epidemiological information were obtained by case 
interviews and review of medical records.  
 Samples for virological confirmation and genotyping of cases were 
collected as established in the Measles Elimination plan guidelines and 
delivered to the Microbiology Department of the H Clinic of Barcelona. 
Serum samples were collected after 3rd day of onset and measles specific 
antibodies IgG and IgM were determined by an ELISA Assay (Vircell 
®
). 
Nasopharyngeal and urine samples were collected and tested by real-time 
RT-PCR. In accordance with WHO recommendation for molecular 
epidemiology of measles, phylogenetic analysis of the 450 nucleotides that 
code for the carboxy-terminal 150 amino acids of the measles nucleoprotein 
(N) gene was used for genotype determination. Sequences obtained during 
this study were submitted to Health Protection Agency (HPA) measles 
database. Statistical assessment of incidence rates (IR) and risk ratios (RR) 
and their 95%CI, hospitalization rate (HR) by age group were determined. 
Statistic Chi
2
, Fisher’s test and statistic z were used for comparing variables 
and proportions. Statistical analysis was performed by means of the SPSS® 
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18.0 statistical package for windows (SPSS; Chicago, USA). Statistical 
significance set at α=0.05. 
 
2. Results 
  
 During the study period 489 suspected measles cases were notified to the 
corresponding regional epidemiological surveillance units versus (vs) 549 in 
the 2006-2007 outbreak. Total number of confirmed cases was 305 vs 381 in 
2006; showing slight statistical difference in confirmation rates (62.4% vs 
69.1%) [OR:0.73;95%CI: 0.56-0.95; (p=0.02)]. Difference in global IR 
showed statistical significance (4.05/100,000 vs 6.6/100,000; (RR: 1.3 
95%CI 1.08-1.46). Mean age of cases was 20 yrs in 2010 (SD 14.8 yrs; range 
3m-51yrs) vs 15m (SD13.1yrs; range 1m-50yrs) in 2006.  Highest proportion 
of cases was set in ≥    25 yrs (47.4%) in 2010 vs 24.2% in 2006 (p<0.001). 
Statistically significant differences were also observed in IR for ≤ 15m 
(49/100,000 vs 278.2/100,000; (RR: 3,9; 95%CI 2.9-5.4) (Fig. 1)  and  in HR  
29.8% vs 15.7%  (OR:2.3;95%CI: 1.54-3.45). 
 The highest percentage of hospitalized patients occurred in those older 
than 25yrs was 37.4 % vs 25.0 % in 2006 [OR:1.79;95%CI: 1.01-3.18 
(p=0.05)] (Table 1). Eighty percent of hospitalized cases presented complications 
 
 
 
Figure 1. Differences in incidence rates of confirmed measles cases of two outbreaks  
according to age group. Catalonia 2006-2007 and 2010-2011 outbreaks [15]. 
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Table 1. Differences in hospitalization rates of confirmed measles cases of two 
outbreaks  according to age group. Catalonia, 2006-2007 and 2010-2011 outbreaks 
[15]. 
 
 
Age group 
Hospitalization rate 
2006-2007 outbreak 
n            % 
Hospitalization rate 
2010-2011 outbreak 
n            % 
OR  
(95%CI) 
p 
≤15m /12m* 25/190       13.2% 12/44         27.3% 
2.48 
(1.14-5.38) 
0.04 
1-4 yrs 5/66        7.6%   4/35         11.4% 
1.57 
(0.42-5.85) 
0.72** 
5-14 yrs 4/23        17.4% 5/27          18.5% 
1.07 
(0.27-4.29) 
1** 
15-24 yrs 3/10        30.0% 15/52         28.8% 
0.95 
(0.23-3.78) 
1** 
>25  yrs 23/92        25.0%  55/147       37.4% 
1.79 
(1.01-3.18) 
0.05 
Total 60/381       15.7% 91 /305         29.8% 
2.3 
(1.54-3.45) 
<0.001 
 
 
 *Below first dose vaccination age ;** Fisher’s exact  Test  
 
in contrast to 58.3% in the 2006 outbreak, being gastrointestinal 
symptoms such as diarrhea and vomiting (33%) the most frequent. A 
higher, although not significant, proportion of pneumonia was observed 
(23 cases: 26%) when compared to 2006 (8 cases: 13.3%) [OR: 1.90; 
95%CI: 0.74-4.96 (p=0.21)]. 
 Laboratory testing was performed in 452 out of 489 suspected cases 
(92.4%) and of these 262 (58%) were confirmed cases and 190 were 
classified as non measles cases. Of the 262 laboratory confirmed cases, 
238 (90.8%) were positive for MV by real-time RT-PCR, 81 (31%) were 
positive for IgM measles specific antibodies and 54 (20.6%) cases were 
both positive for real-time RT-PCR and IgM. Seventy percent of cases 
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were confirmed on basis of positive urine and/or pharyngeal swab 
positive RT-PCR  MV test whereas in the 2006 outbreak this percentage 
accounted for only 19.7% of laboratory confirmed cases. 
 Phylogenetic analysis of the minimum recommended 450 nucleotides 
of N gene of 227/238 (91%) out of all RT-PCR positive samples revealed 
that the strains belonged to six different genotypes: A (3; 1.6%), B3 (147; 
59.5%), D4 (66; 33.2%), D8 (7; 2.8%), D9 (6; 2.4%) and G3 (1; 0.4%) 
(Fig. 2). 
 Genotype A was related to vaccine-induced virus infection. Two 
hundred and seventy one cases /305 (89%) were unvaccinated people of 
these 36/271 (13.3%) cases were below vaccination age (12 m) and 32 
(11.8%) refused vaccination on philosophical beliefs. Twenty six cases 
(8%) had one dose and 8 (3%) had 2 doses. One of these cases vaccinated 
with 2 doses of MMR occurred in a physician working at a                              
hospital emergency department. Seventy eight cases were of foreign                                                           
origin (25.3%) vs 39 (10.2%) in the 2006 outbreak [OR: 2.90;                        
95%CI: 1.87-4.53 (p<0.001)]; and 11 cases (3.6%) occurred in healthcare 
settings vs 11(2.9%)in the 2006 outbreak [OR: 1.25; 95%CI: 0.50-3.17 
(p=0.75)].   
 
 
 
Figure 2. Distribution of genotypes according to week of onset of confirmed cases. 
Catalonia 2010-2011 outbreak [15]. 
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3. Discussion 
  
 The increase in measles cases in 2010 occurred despite a steady rise in 
regional and global MMR coverage. Measles surveillance data and outbreak 
investigations provide critical information to identify gaps in population 
immunity and lead to corrective actions and refinements of vaccination 
strategies. 
 Adapting vaccination strategies to the epidemiological scenario is 
important to control of the disease, thus with the evidence gathered from one 
large outbreak [14], infants have been spared from measles infection in this 
second  large outbreak four years later when other European countries have had 
high incidence in infants below vaccination scheduled age [8,16-19]. 
Surveillance data analyses and outbreak investigations should continue to be 
used to complement vaccination coverage monitoring to identify gaps in 
vaccination programs [20]. Yet measles transmission has been firmly                     
re-established in some European Union (EU) Member States to the extent of  
even exporting measles to the rest of the world, threatening to undermine years 
of efforts to eliminate endemic transmission of the measles virus [10,21]. 
 The difference in global hospitalization rate (29.8% vs 15.7%) and higher 
proportion of  complications (80% vs 53.7%) could be explained by the 
higher proportion of adult cases affected in this second outbreak in which the 
mean age of cases was 20 yrs (SD 14.8 yrs; range 3m-51yrs) vs 15m in the 
2006 outbreak [22]. Yet hospitalization rate in infants below vaccination age 
was still high (27.3% vs 13.2%) compared to the previous and other  
outbreaks [23]. This could reflect a higher sensitivity and therefore higher 
degree of hospitalization not solely on severity of disease. Although further 
studies should explore whether the fact that cases were infected by different 
genotypes that might also have different severity.   
 The implementation of molecular diagnostic and genotyping techniques 
allowed to gathering epidemiological information on measles virus 
circulating types. Genotypes B3 and D4 were the predominant genotypes in 
the second measles outbreaks in Catalonia while the first was entirely 
identified as genotype D4 [24].
 
 Genotypes B3 and D4 showed genetic differences between sequences 
with a maximum genetic distance of 2 nucleotides in the genomic region 
studied, revealing different genetic viral variants within the same genetic 
group. The remaining genotypes D8 and D9 appeared in sporadic cases or 
related to small limited outbreaks during the study period. Measles genotype 
G3 is generally associated with measles infections in south-east Asia, or in 
sporadic cases with links to south-east Asia [25]. There had been no reported 
Núria Torner et al.  94 
cases of measles G3 in Europe since 2006 until by the end of 2010 it 
reappeared in several different countries in Europe [26]. Unlike other 
outbreaks [14,16,27] six different genotypes have been isolated in Catalonia 
during the study period, showing several importations as a result of the  high 
incidence in other neighboring territories. 
 The high proportion of cases in immigrant population (24.9%) reflects 
the fact that, although immigrants are offered the same health care services as 
the indigenous population, the rate of MMR vaccination coverage is lower in 
this population [28]. In the 2006 outbreak, this proportion was significantly 
lower (10.2%) probably because immigrant parents do adhere to pediatric 
vaccination schedules in a greater proportion than adults. This fact stresses 
the need to offer complete adult vaccination schedule to this population when 
consulting primary care services.  
 Although nosocomial infection has been described as an important 
source for measles infection [19,29], in this, as in the previous  outbreak, only 
11 cases (3.6% and 2.9% respectively) were related to healthcare workers 
with few secondary cases arising from them, this fact underscores the 
importance of maintaining high MMR immunization coverage and of  the 
efforts addressed to improve this coverage in order  to reach zero cases in 
healthcare workers in future outbreaks.  
 First cases identified in this 2010-2011 outbreak occurred within a setting 
of  unvaccinated children due to philosophical reasons (11.8%) giving place 
to transmission in an area where anti-vaccine movement is active. This was 
not so in the previous outbreak where rejection of vaccination for 
philosophical reasons  (1.5%) would not have greatly influenced maintained  
transmission of chains [14]. Parents who refuse to vaccinate their children are 
an important issue because of the influence it can have on sustaining 
transmission after an importation of MV within a community. Several authors 
have studied this phenomenon to find out which are the keys to this belief 
[30,31]. The anti-vaccine movement represents ongoing groups who share 
concerns based on misconceptions, unfortunately, they not only put their own 
children at higher risk for disease but they also contribute to the failure of 
communities to achieve protective vaccination rates and to herd immunity 
failure even among highly vaccinated populations [32]. 
 The  fact that a physician correctly vaccinated with 2 doses of MMR 
became  ill has also been observed by other authors [33]. It might indicate 
that in an outbreak setting with persistent close contact with MV, waning of 
immunity over time is another issue to be followed up closely, especially in 
regions where circulation of wild MV is low and could pose the possibility of 
recommending a booster dose for healthcare workers  in an outbreak setting 
[34,35]. 
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 Since the interruption of endemic measles transmission in December of 
2000 and in spite of the high-immunization coverage, measles outbreaks and 
sporadic infections have occurred in Catalonia due to importations of 
measles, yet no sustained transmission had occurred and outbreaks, to the 
exception of those described in this study, were quickly set under control. 
Surveillance data and results of molecular epidemiology indicate that there is 
a continuous exposure to MV from other regions of Europe and of the world. 
The co-circulation of different genotypes and several viral variants for 
genotypes B3 and D4 revealed that 2010-2011 outbreak was caused by 
multiple imports from abroad or other Spanish regions (Andalusia, Madrid) 
and confirms the absence of endemic infection. The change of the month of 
administration of the first dose proved successful in preventing disease and 
hospitalization in unvaccinated infants, but young adult population are far 
harder to reach than children. In this pouch of susceptible, achieving high 
coverage is difficult and furthermore they are the most mobile population, 
greatly prone to travel and be a source for importation themselves.  
 
4. Conclusion 
 
 Elimination and eradication programs are laudable goals, but they carry 
with them an awesome responsibility. There is no room for failure. Careful 
and deliberate evaluation is a prerequisite before embarking on any program. 
Elimination and eradication are the ultimate goals of public health. The only 
question is whether these goals are to be achieved in the present or some 
future generation. 
 In conclusion, given the current epidemiological situation, continued 
awareness and efforts to reach young adult population (especially healthcare 
workers and travelers) are needed to stop the spread of the virus. Enhanced 
measles surveillance is critical to disease control by early identification of 
measles cases and thus allowing for early detection and control of outbreaks, 
assessing on-going transmission patterns in order to mount more effective 
vaccination measures. 
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